Financial News

Financial Report: Johnson & Johnson

Pharmaceutical sales up 4% in the quarter and for the year

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson

4Q Revenues: $20.7 billion (+2%)

4Q Earnings: 4.0 billion (+32%)

FY Revenues: $82.1 billion (+1%)

FY Earnings: $15.1 billion (-1%)

Comments: Pharmaceutical sales were $10.5 billion in the quarter, up 4%. For the year pharmaceutical sales were $42.2 billion, up 4%. Growth for the year was driven by STELARA for the treatment of immune-mediated inflammatory diseases, DARZALEX for the treatment of multiple myeloma, IMBRUVICA for treating certain B-cell malignancies, TREMFYA for the treatment of moderate to severe plaque psoriasis, INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA for the treatment of schizophrenia, and ERLEADA, a next-generation androgen receptor inhibitor for the treatment of prostate cancer. Growth was partially offset by biosimilar and generic competition, primarily declines in REMICADE, U.S. ZYTIGA and international VELCADE.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters